| |
著者: Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Tomita Y, Kamide Y, Tsuburai T, Sekiya K, Ishii M, Hasegawa Y, Taniguchi M.
雑誌名: J Allergy Clin Immunol. 2023 Jun;151(6):1667-1672.e2. doi: 10.1016/j.jaci.2023.03.014. Epub 2023 Mar 24.
Abstract/Text
BACKGROUND: Omalizumab, an anti-IgE antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extrarespiratory (chest, gastrointestinal, and/or cutaneous) symptoms, which are resistant to conventional treatment but can be alleviated by systemic corticosteroids.
OBJECTIVE: We evaluated the efficacy of omalizumab on extrarespiratory symptoms related to AERD.
METHODS: In study 1, a total of 27 consecutive patients with AERD initially prescribed omalizumab at Sagamihara National Hospital between July 2009 and March 2019 were retrospectively studied. Frequency of exacerbations of AERD-related extrarespiratory symptoms was compared before and after omalizumab treatment. In study 2, we reported 3 AERD cases with aspirin challenge-induced extrarespiratory symptoms among patients studied in our previous randomized trial (registration UMIN000018777), which evaluated the effects of omalizumab on hypersensitivity reactions during aspirin challenge to AERD patients. Extrarespiratory symptoms induced during the aspirin challenge were compared between placebo and omalizumab phases.
RESULTS: In study 1, omalizumab treatment was associated with decrease in frequency of exacerbation of chest pain (no. [%] of patients with exacerbation frequency ≥1 time per year, 6 [22.2%] vs 0; P < .001), gastrointestinal symptoms (9 [33.3%] vs 2 [7.4%]; P = .016), and cutaneous symptoms (16 [59.3%] vs 2 [7.4%]; P < .001), even under conditions of treatment-related reduction in systemic corticosteroid dose. Omalizumab also attenuated all the extrarespiratory symptoms during aspirin challenge in study 2.
CONCLUSION: Omalizumab ameliorated extrarespiratory symptoms at baseline (without aspirin exposure) and during aspirin challenge.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
PMID 36967017 J Allergy Clin Immunol. 2023 Jun;151(6):1667-1672.e2. doi: 10.1016/j.jaci.2023.03.014. Epub 2023 Mar 24.
|
